• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多药耐药性:难治性幽门螺杆菌感染的临床困境。

Multidrug resistance: The clinical dilemma of refractory Helicobacter pylori infection.

机构信息

Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; College of Medicine, Chang Gung University, Taoyuan, Taiwan; Chang Gung Microbiota Therapy Center, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.

Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.

出版信息

J Microbiol Immunol Infect. 2021 Dec;54(6):1184-1187. doi: 10.1016/j.jmii.2021.03.006. Epub 2021 Mar 23.

DOI:10.1016/j.jmii.2021.03.006
PMID:33840604
Abstract

This study investigated the antimicrobial resistance of isolates from patients with refractory Helicobacter pylori. The resistance rate was 34.1% for amoxicillin, 92.7% for clarithromycin, 65.9% for metronidazole, 85.4% for levofloxacin, and 29.3% for rifabutin. Dual resistance to both clarithromycin and levofloxacin was found in 73.2%. The antimicrobial resistance rate of refractory H. pylori was extremely high, which had become a major consideration in therapeutic challenge.

摘要

本研究调查了耐治疗性幽门螺杆菌患者分离株的抗菌药物耐药性。阿莫西林的耐药率为 34.1%,克拉霉素 92.7%,甲硝唑 65.9%,左氧氟沙星 85.4%,利福布汀 29.3%。同时对克拉霉素和左氧氟沙星耐药的比例为 73.2%。耐治疗性幽门螺杆菌的抗菌药物耐药率极高,这已成为治疗挑战的主要考虑因素。

相似文献

1
Multidrug resistance: The clinical dilemma of refractory Helicobacter pylori infection.多药耐药性:难治性幽门螺杆菌感染的临床困境。
J Microbiol Immunol Infect. 2021 Dec;54(6):1184-1187. doi: 10.1016/j.jmii.2021.03.006. Epub 2021 Mar 23.
2
Increasing antimicrobial resistance to clarithromycin and metronidazole in pediatric Helicobacter pylori infection in southern Taiwan: A comparison between two decades.台湾南部儿童幽门螺杆菌感染中克拉霉素和甲硝唑耐药性的增加:二十年的对比。
Helicobacter. 2019 Oct;24(5):e12633. doi: 10.1111/hel.12633. Epub 2019 Jul 11.
3
Broad spectrum resistance in Helicobacter pylori isolated from gastric biopsies of patients with dyspepsia in Cameroon and efflux-mediated multiresistance detection in MDR isolates.在喀麦隆消化不良患者的胃活检中分离出的幽门螺杆菌的广谱耐药性和 MDR 分离株中流出介导的多药耐药性检测。
BMC Infect Dis. 2019 Oct 22;19(1):880. doi: 10.1186/s12879-019-4536-8.
4
Resistance rate to antibiotics of Helicobacter pylori isolates in eastern Taiwan.台湾东部幽门螺杆菌分离株的抗生素耐药率。
J Gastroenterol Hepatol. 2007 May;22(5):720-3. doi: 10.1111/j.1440-1746.2006.04743.x.
5
Antimicrobial resistance among Helicobacter pylori isolates in Alaska, 2000-2016.2000-2016 年期间,阿拉斯加分离的幽门螺杆菌菌株的耐药情况。
J Glob Antimicrob Resist. 2018 Dec;15:148-153. doi: 10.1016/j.jgar.2018.06.016. Epub 2018 Jun 30.
6
In vitro antimicrobial susceptibility of Helicobacter pylori to nine antibiotics currently used in Central Italy.意大利中部目前使用的九种抗生素对幽门螺杆菌的体外抗菌敏感性
Scand J Gastroenterol. 2016 Mar;51(3):263-9. doi: 10.3109/00365521.2015.1092577. Epub 2015 Oct 7.
7
Primary and secondary antibiotic resistance of Helicobacter pylori in Korea from 2003 to 2018.韩国 2003 年至 2018 年幽门螺杆菌的初级和次级抗生素耐药性。
Helicobacter. 2019 Dec;24(6):e12660. doi: 10.1111/hel.12660. Epub 2019 Sep 11.
8
Primary and secondary clarithromycin, metronidazole, amoxicillin and levofloxacin resistance to Helicobacter pylori in southern Poland.波兰南部幽门螺杆菌对克拉霉素、甲硝唑、阿莫西林和左氧氟沙星的原发和继发耐药性。
Pharmacol Rep. 2011;63(3):799-807. doi: 10.1016/s1734-1140(11)70592-8.
9
Dynamics of antimicrobial resistance of Helicobacter pylori isolates in the Smolensk region of Russian Federation.俄罗斯联邦斯摩棱斯克地区幽门螺杆菌分离株的抗菌药物耐药性动态。
Helicobacter. 2018 Dec;23(6):e12545. doi: 10.1111/hel.12545. Epub 2018 Oct 16.
10
Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection.基于培养的选择疗法用于治疗先前对幽门螺杆菌感染治疗无反应的患者。
Clin Gastroenterol Hepatol. 2013 May;11(5):507-10. doi: 10.1016/j.cgh.2012.12.007. Epub 2012 Dec 23.

引用本文的文献

1
Tailored therapy guided by genotypic resistance from gastric mucosa samples in the first-line treatment of infection: a systematic review and meta-analysis.基于胃黏膜样本基因型耐药指导的一线治疗感染的个体化疗法:一项系统评价和荟萃分析。
Therap Adv Gastroenterol. 2025 Jun 26;18:17562848251348826. doi: 10.1177/17562848251348826. eCollection 2025.
2
The Aging Stomach: Clinical Implications of Infection in Older Adults-Challenges and Strategies for Improved Management.衰老的胃:老年人感染的临床意义——改善管理的挑战与策略
Int J Mol Sci. 2024 Nov 28;25(23):12826. doi: 10.3390/ijms252312826.
3
Insights into macrolide resistance: a comprehensive systematic review and meta-analysis.
大环内酯类耐药性研究进展:一项全面的系统评价与荟萃分析
Front Microbiol. 2024 Oct 30;15:1481763. doi: 10.3389/fmicb.2024.1481763. eCollection 2024.
4
Unveiling the Antibacterial Properties of Statins: An Study on .揭示他汀类药物的抗菌特性:一项关于……的研究
Adv Pharmacol Pharm Sci. 2024 Aug 12;2024:6380155. doi: 10.1155/2024/6380155. eCollection 2024.
5
The Role of Probiotics in the Eradication of Helicobacter pylori and Overall Impact on Management of Peptic Ulcer: A Study Involving Patients Undergoing Triple Therapy in Bangladesh.益生菌在根除幽门螺杆菌中的作用及对消化性溃疡治疗的总体影响:一项针对孟加拉国接受三联疗法患者的研究
Cureus. 2024 Mar 16;16(3):e56283. doi: 10.7759/cureus.56283. eCollection 2024 Mar.
6
Analysis of Helicobacter pylori resistance in patients with different gastric diseases.分析不同胃部疾病患者的幽门螺杆菌耐药性。
Sci Rep. 2024 Feb 28;14(1):4912. doi: 10.1038/s41598-024-55589-2.
7
Effectiveness of Rifabutin-Based Regimens in Treating Helicobacter pylori Infections.基于利福布汀的治疗方案对幽门螺杆菌感染的疗效
Cureus. 2023 Dec 14;15(12):e50541. doi: 10.7759/cureus.50541. eCollection 2023 Dec.
8
Antibiotic resistance of in Nanjing, China: a cross-section study from 2018 to 2023.中国南京耐抗生素不动杆菌的耐药性:2018 年至 2023 年的横断面研究。
Front Cell Infect Microbiol. 2023 Nov 28;13:1294379. doi: 10.3389/fcimb.2023.1294379. eCollection 2023.
9
Drug-Resistant : Diagnosis and Evidence-Based Approach.耐药性:诊断与循证方法
Diagnostics (Basel). 2023 Sep 14;13(18):2944. doi: 10.3390/diagnostics13182944.
10
Current paradigms in the management of refractory Helicobacter pylori infection.难治性幽门螺杆菌感染的当前管理范式。
Indian J Gastroenterol. 2023 Dec;42(6):766-779. doi: 10.1007/s12664-023-01448-3. Epub 2023 Sep 22.